Some β 2 -adrenergic agonists (β 2 -agonists) can strongly induce muscular hypertrophy, and are prohibited to use as doping drugs for athletes. The pharmacological mechanism for such induced hypertrophy is not clear. These agonists affect many organs via the cAMP-PKA system. Muscular hypertrophy is most likely induced by way of protein synthesis via the IGF-1/PI3K/ PKB system and negative myostatin pathway. There are some reports indicating that β 2-agonists might stimulate protein synthesis via the IGF-1/PI3K/PKB system. Furthermore, it inhibits proteolysis via the ATP-dependent ubiquitin-proteasome system (UPS), autophagy-lysosome system and calcium-calpain system. In this review, some discrepancies are introduced between a basic hypertrophic mechanism and inhibited atrophic mechanism using β2-agonists. Surfaces of muscle fiber might have some various receptors, and the β2-adrenoceptor might be activated directly by PI3K via Gαs to trigger skeletal muscle hypertrophy. β2-agonists might be stimulated to synthesize follistatin of the myostatin inhibitor, as well as to produce satellite cells. Furthermore, increased myostatin may work to determine the size of each muscle fiber, and an increased number of quiescent satellite cells serve as myonuclei donors for hypertrophied muscle fibers. Recently, it was reported that follistatin synthesis was regulated by microRNAs. The effect of microRNA on β2-agonists is not clear. In the cAMP/PKA/CREB pathway, β2-agonists might inhibit various proteolytic systems, resulting in an increase of structural proteins. But β2-agonists have more pharmacological functions like lipolytic action and stimulation of the central nervous system; thus, more research and analysis is needed.
Introduction
Muscular hypertrophy is one of the most interesting phenomena for athletes and people with muscle-wasting disorders. There are many methods to induce muscular hypertrophy like anaerobic weight training and hormonal treatment. Some β2-adrenergic agonists (β2-agonists) like clenbuterol, fenoterol, formoterol and salbutamol are well known as bronchodilators to treat asthma, and act as decongestants or as powerful anabolic agents. Therefore, they are limited in use for doping in athletic competitions. In particular, the anabolic action is the most intrinsic property in sports. Over the past 30 years many investigators have reported about skeletal and/or cardiac muscle hypertrophy with clenbuterol administration [1] [2] [3] [4] [5] . But the mechanism of the action of drugs is complicated, and still under discussion in some reviews [6] [7] [8] [9] .
In this review, I propose a way to clarify the problem of the mechanism. The basic idea to explain muscular hypertrophy is due to the increased structural proteins. It was caused by the increased protein synthesis and the decreased proteolysis. The homeostatic protein content is maintained by the balance between synthesis and breakdown. The grade of change is summarized into hypertrophic grades (H1-H4), atrophic grades (A1-A4) or keeping the situation (K) with no change (Table 1 ). If both the increasing grade and the degradation grade are the same high level (I5 and D5), protein content shows no change (K). Therefore, we need a few analyses to determine atrophy or hypertrophy in two different directions. But most research was done in one direction for the various reasons of time, technique, and so on.
In many cases, increasing grades (I1-I5) depend on the activity of the IGF-1/PI3K/Akt signaling pathway [10] [11] [12] and negative myostatin pathway for protein synthesis [13] [14] [15] . On the other hand, degradation grades depend on the activity of the ATP dependent ubiquitin-proteosome system (UPS) 16, 17) , autophagy-lysosome system [18] [19] [20] and calcium sensitive calpain pathway [21] [22] [23] . They are well documented by Ito et al. 24) . synthesis via the IGF-1/PI3K/Akt pathway in striated muscles [25] [26] [27] [28] [29] . Although β2-agonists do not bind to IGF receptors directly, clenbuterol causes a transient increase of IGF-I in cells 30) and of IGF-II in rat soleus 29) and masseter muscle 31) . The IGF-1/PI3K/Akt pathway might be stimulated by increased IGFs. The peptide hormone ghrelin 32) , which increases before meals and decreases after meals, is secreted from the stomach and the hypothalamus, where it stimulates the secretion of growth hormone (GH) from the anterior pituitary gland. Then GH promotes IGF-1 synthesis and muscle growth. However, the increasing mechanism of IGFs by clenbuterol remain to be resolved. Spurlock et al. 33) showed that clenbuterol promotes the synthesis of IGF-1 mRNA-related muscle growth in mouse gracilis muscle. β2-agonists activate the guanine nucleotide exchange factor domain of the β2adrenoceptor causing the exchange of GDP for GTP at the α stimulatory subunit of the guanine nucleotide-binding regulatory protein (Gαs) and the subsequent dissociation of Gαs from the tightly associated β and γ subunits (Gβγ). 34) . And activation of frizzled (Fzd) 7, another member of the G protein coupled receptor family, induced hypertrophy of rodent myotubes via the activation of the PI3K-Akt-mTOR pathway. Gαs-coupled receptors expressed in skeletal muscle were summarized and reported by Berdeaux and Stewart 8) ( Fig. 1 ). It may suggest that β2-adrenoceptor might be able to directly activate PI3K via Gαs to trigger skeletal muscle hypertrophy. Skeletal muscle hypertrophy was explained by hypertrophy of individual muscle fibers and hyperplasia increasing the number of cells. The former was supported by the increased diameter of muscle fibers; the latter by the increased number of fibers. Increased mRNA and protein content of muscle structural proteins and growth factor like IGF-1, and decreased mRNA and protein content of proteolytic enzymes may explain the hypertrophy of muscle. Table 1 explains high hypertrophy (e.g. H4) by the high increasing grade (e.g. I5) and low degradation grade (e.g. D1) in muscular change.
It was shown by von Maltzahn et al that Gαs could directly activate PI3K
Myostatin is a member of transforming growth factor beta (TGF-β) and inhibits muscle differentiation and growth in myogenesis ( Fig. 2) . Therefore, decreased myostatin content by varoius stimulations also will explain increased protein synthesis. However, β2-agonists surprisingly showed increased myostatin contents. Therefore, skeletal muscle hypertrophy by β2-agonists should be explained by increased IGF, not by increased myostatin, which may have other functions. Myostatin is expressed in satellite cells and regulates satellite cell quiescence and self-renewal 35) . The adult muscle cells are post-mitotic and unable to divide, they must acquire external DNA. Satellite cells retain their mitotic capacity 36) . Higher levels of myostatin have been observed in quiescent satellite cells 37) . It may mean that an increasing number of quiescent satellite cells serve as myonuclei donors for hypertrophied muscle fibers and support preferential increments of DNA content in the latter phase of hypertrophy with β-agonist Cimaterol 38) . In the cAMP/PKA/CREB pathway, the major effector of cAMP in skeletal muscle is protein kinase A (PKA). β2agonists bind their own receptors and increase cAMP on PKA regulatory subunits, leading to the release of PKA catalytic subunits, which then drive cAMP response element binding protein (CREB) phosphorylation on Ser133. CREB phosphorylation occurs rapidly in skeletal muscle in response to β2--agonist administration 27) . Many genes contain cAMP response elements, and are thus potential targets of CREB 39) . CREB stimulates retinoblastoma protein promoter activity, together with MyoD, to induce the differentiation of myoblasts into myotubes 40) . CREB interacts with MyoD on follistatin promoter, thus promoting follistatingene expression 41) (Fig. 2 ). Follistatin also known as an activin-binding protein is a protein that in humans is encoded by the FSTgene and inhibits excessive muscle growth. Follistatin has been shown to induce skeletal muscle hypertrophy, notably by inhibiting myostatin activity 42, 43) . Follistatin-mediated skeletal muscle hypertrophy is regulated by Smad3 and mTOR independently of myostatin. Modulation of myostatin activity by follistatin could therefore contribute to the hypertrophy and anti-atrophy effects of β2-agonists. Gilson et al. 44) showed that the IGF-IR/Akt/mTOR pathway plays a critical role in follistatin-induced muscle hypertrophy. There are various kinds of follistatin, which have different functions. It is said that only follistatin-344 is active in muscle tissue.
Recently, it was reported that a few microRNAs (miR-NAs or miRs) regulate skeletal muscle hypertrophy [45] [46] [47] [48] [49] . For example, Clop et al. 50) introduced that miR-1 and miR-206 were important in muscular hypertrophy causing translational inhibition of myostatin gene. Sun Y et al. 51) showed that mTOR regulated miR-1 and follistatin, i.e. the mTOR-miR-1-HDAC4-follistatin pathway. These might bring a novel explanation of muscular hypertrophy by β2-agonists.
Decrement of structural proteins
On the ubiquitin-proteosome system, two typical E3 ubiquitin (Ub) ligases, atrogin-1 and muscle ring-finger protein 1 (MuRF-1), are important in regulating the contents of MyoD and myosin, respectively, and are activated by the FOXO transcription factors (Fig. 2) . Bodin et al. 16) and Sandri et al. 17) showed Akt-mTOR pathway protein degradation via inhibition of the ubiquitin proteasome system (UPS). Costelli et al. 52) demonstrated that clenbuterol treatment suppresses the expression of ubiquitin (Ub) mRNA in rats. And Gonçalves et al. 53) suggested that clenbuterol inhibited atrogin-1 expression. Recently Ijiri et al. 54) reported that clenbuterol induced muscle hypertrophy of neonatal chicks owing to decreased atrogin-1 mRNA. In the autophagy system, the breakdown of proteins is necessary for amino acid turnover for maintaining normal cellular function. Zhao et al. 55) showed that inhibition of FOXO3 by activated Akt promotes skeletal muscle loss via the coordinate activation of both UPS and autophagy. Furthermore, the calcium-calpain system also plays important roles for protein turnover. Gonçalves et al. 19) showed clenbuterol suppresses proteasomal and lysosomal proteolysis in rat soleus muscles. With clenbuterol, Douillard et al. 56) showed the inhibition of calpain proteinase in rat skeletal muscles, and Higgins et al. 21) showed the inhibited activity of calpain in lambs. Even if proteolysis is activated by β2-agonists, more activated protein synthesis will produce more structural proteins with their own fragmented amino acids and amino acids from foods. It is just like I4 and D3 representing hypertrophy (H1) in grade of muscular change (Table 1) .
Conclusion
It is true that muscular hypertrophy is induced by β2agonists. The medical use of drugs may bring many benefits for many patients. The pharmacological mechanisms and effects of β2-agonists on skeletal muscle are becoming clearer, in part, due to new analyzing methods for analysis of signaling pathways and downstream effectors regulating protein homeostasis. However, undesirable side effects like cardiac muscle damage and hypertension from the drugs must be taken into account. More novel trials like miRNA function analysis may help to elucidate the mechanism of muscular hypertrophy and other pharmacological functions.
